FULC

Equibles Rating blended score · not investment advice

Overall

Sell

Technical · trend & momentum Sell

◦ 50 / 200-day cross no cross

− Price vs 200-day avg −56% below

− Price vs 50-day avg −31% below

◦ RSI (14) 38 · neutral

+ MACD trend positive

− 52-week position 7% · near low

Sentiment · smart money Neutral

◦ Trend (MA cross) 50d $5 › 200d $8 — 200d above 50d

− Institutional flow -2% holders QoQ · +36 funds added

− Insider flow Net -$65.6K over 90 days · 100% sells

+ Short interest 8.29% of float · ▼ -30.9% MoM · 1.0 days cover

◦ Volume signal Volume near normal

+ Institution breadth 168 holders — near 3-yr high, broad support

Fundamentals Weak

− EPS growth −638% Y/Y

− Free cash flow $-60.4M

+ Balance sheet net cash $197.5M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next

Next earnings call

Jul 27, 2026 Est · unconfirmed · in 3 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Apr 27, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Technicals

trend & momentum for long-term holders Sell

3 · 2 · 1

50 / 200-day cross

no cross Neutral

Price vs 200-day avg

−56% below Bearish

Price vs 50-day avg

−31% below Bearish

RSI (14)

38 · neutral Neutral

MACD trend

positive Bullish

52-week position

7% · near low Bearish

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $5 › 200d $8 — 200d above 50d

Institutional flow Distributing

-2% holders QoQ · +36 funds added

Insider flow Distributing

Net -$65.6K over 90 days · 100% sells

Short interest Falling

8.29% of float · ▼ -30.9% MoM · 1.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

168 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $3 Now $4 · 7% 52-wk high $16

vs 200-day avg -56% vs 50-day avg -31%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
cash, cash equivalents, and marketable securities	$333.3M	first quarter of 2026	—
HbF at baseline	7.1%	Phase Ib PIONEER trial call	—
HbF at week 12	19.3%	Phase Ib PIONEER trial call	—
patients with no VOCs during treatment period	7	Phase Ib PIONEER trial call	—
total patients evaluated for VOCs	12	Phase Ib PIONEER trial call	—
Mean absolute HbF increase from baseline at Week 12 (20 mg cohort)	12.2%	PIONEER Phase 1b 20 mg cohort, Week 12	—
Net proceeds from December 2025 public offering	$164.2M	December 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
FULC Fulcrum Therapeutics, Inc. this stock	$247.88M	-67.1%	—	—	8.3%
ONC BeOne Medicines Ltd.	$488.96B	+1.9%	+22179.2%	995.1	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$132.92B	+16.8%	+46.2%	31.1	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$69.33B	-15.7%	+20.8%	16.1	3.2%
ARGX Argenx SE	$57.87B	+9.0%	—	—	2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

168

% held: 107.8%
Net QoQ: +3.9M sh
Top holder: SUVRETTA CAPITAL MANAGEME…

Held Float

View

Held by Funds

Fund positions

154

View

Short & Settlement

Short Interest Falling

Shares short

5.5M

Days to cover: 1.0d
Change: -2.5M sh

View

Short Volume

Short vol %

21%

As of: Jul 7, 2026

Short Total

View

Fails to Deliver

FTD shares

19.4K

Value: $68.1K
As of: Jun 11, 2026

View

Off-Exchange

Off-exchange %

42.4%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$65.6K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Net income (FY)

$-74.9M

EPS diluted: $-1.18

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 25, 2026
This year: 10

View

Proposed Sales

Value

$65.0K

Shares: 18.0K
Filed: Jun 26, 2026

View

Exempt Offerings

Offering

$68.5M

Filed: Jun 11, 2020

View

Earnings & Events

Earnings Calls

Last call

Apr 27, 2026

View

Performance

	5D	20D	120D	MTD	YTD
FULC	-2.1%	+10.4%	-62.2%	+1.6%	-67.1%
SPY	+3.1%	-0.8%	+8.2%	+0.6%	+10.2%
vs SPY	-5.2%	+11.2%	-70.5%	+1.0%	-77.3%

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance